인플루엔자 치료제 시장 : 세계 업계 분석, 규모, 점유율, 성장, 동향 및 예측(2023-2031년)
Influenza Medication Market (Product: Zanamivir, Oseltamivir, Peramivir, Amantadine, Rimantadine, Inosine, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
상품코드:1420995
리서치사:Transparency Market Research
발행일:2023년 12월
페이지 정보:영문 159 Pages
라이선스 & 가격 (부가세 별도)
한글목차
인플루엔자 치료제 시장 - 리포트의 범위
세계의 인플루엔자 치료제 시장에 관한 TMR의 리포트는 과거와 현재의 성장 동향 및 2023-2031년의 예측 기간 중 시장 지표의 귀중한 인사이트를 얻을 기회를 연구하고 있습니다. 이 리포트는 세계의 인플루엔자 치료제 시장 매출을 제공하고, 2017-2031년의 기간, 2023년을 기준년, 2031년을 예측년으로 간주합니다. 이 리포트는 2023-2031년 세계의 인플루엔자 치료제 시장의 연평균 성장률(CAGR %)도 제공합니다.
이 리포트는 광범위한 조사를 거쳐 작성되었습니다. 1차 조사에서는 조사 활동의 대부분이 시행되고, 애널리스트가 주요 오피니언 리더, 업계 리더, 오피니언 제조업체와 인터뷰를 시행했습니다. 2차 조사에는 인플루엔자 치료제 시장을 이해하기 위해 주요 기업의 제품 문헌, 연차보고서, 프레스 릴리스 및 관련 문서의 참조가 포함됩니다.
시장 스냅숏
2023년 시장 가치
9억 700만 달러
2031년 시장 가치
11억 달러
CAGR
2.2%
이 리포트는 세계의 인플루엔자 치료제 시장의 경쟁 구도를 상세히 파악하고 있습니다. 세계의 인플루엔자 치료제 시장에서 활동하는 주요 기업이 식별되고, 각각의 기업이 다양한 속성의 관점으로부터 프로파일링되고 있습니다. 회사 개요, 재무 상황, 최근 동향, SWOT는 이 리포트에서 소개되고 있는 세계의 인플루엔자 치료제 시장 기업의 속성입니다.
목차
제1장 주요 요약
제2장 전제조건과 조사 방법
제3장 주요 요약 : 세계 시장
제4장 시장 개요
시장 세분화
개요
시장 역학
세계 시장의 분석과 예측, 2017-2031년
제5장 주요 인사이트
파이프라인 분석
COVID-19 팬데믹이 업계에 미치는 영향
제6장 시장 분석과 예측 : 제품 유형별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 제품 유형별, 2017-2031
Zanamivir
Oseltamivir
Peramivir
Amantadine
Rimantadine
Inosine
기타(Laninamivir Octanoate 등)
시장의 매력 : 제품 유형별
제7장 세계 시장의 분석과 예측 : 유통 채널별
서론과 정의
주요 조사 결과/발전
시장 금액 예측 : 유통 채널별, 2023-2031
병원
클리닉
약국
기타
시장의 매력 : 유통 채널별
제8장 세계 시장의 분석과 예측 : 지역별
주요 조사 결과
시장 금액 예측 : 지역별, 2017-2031
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
시장의 매력 : 지역별
제9장 북미 시장 분석과 예측
제10장 유럽 시장 분석과 예측
제11장 아시아태평양 시장 분석과 예측
제12장 라틴아메리카 시장 분석과 예측
제13장 중동 및 아프리카 시장 분석과 예측
제14장 경쟁 구도
시장 기업 - 경쟁 매트릭스(기업의 계층 및 규모별)
시장 점유율 분석 : 기업별(2022년)
기업 개요
F. Hoffmann-La Roche Ltd.,
Teva Pharmaceutical Industries Ltd.
Sandoz International GmbH
Sun Pharmaceutical Industries Ltd.
Mylan, Inc.
GlaxoSmithKline plc
Daiichi Sankyo Company
Natco Pharma
KSA
영문 목차
영문목차
Influenza Medication Market - Scope of Report
TMR's report on the global influenza medication market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global influenza medication market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global influenza medication market from 2023 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the influenza medication market.
Market Snapshot
Market Value in 2023
US$ 907 Mn
Market Value in 2031
US$ 1.1 Bn
CAGR
2.2%
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global influenza medication market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global influenza medication market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global influenza medication market.
The report delves into the competitive landscape of the global influenza medication market. Key players operating in the global influenza medication market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global influenza medication market profiled in this report.
Key Questions Answered in Global influenza medication Market Report:
What is the sales/revenue generated by influenza medication across all regions during the forecast period?
What are the opportunities in the global influenza medication market?
What are the major drivers, restraints, opportunities, and threats in the market?
Which regional market is set to expand at the fastest CAGR during the forecast period?
Which segment is expected to generate the highest revenue globally in 2031?
Which segment is projected to expand at the highest CAGR during the forecast period?
What are the market positions of different companies operating in the global market?
Influenza Medication Market - Research Objectives and Research Approach
The comprehensive report on the global influenza medication market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.
For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.
The report analyzes the global influenza medication market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global influenza medication market.
Table of Contents
1. Executive Summary
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Influenza Medication Market
4. Market Overview
4.1. Market Segmentation
4.1.1. Segment Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Influenza Medication Market Analysis and Forecast, 2017-2031
5. Key Insights
5.1. Pipeline Analysis
5.2. COVID-19 Pandemic Impact on Industry
6. Influenza Medication Market Analysis and Forecast, by Product Type
6.1. Introduction and Definitions
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Product Type, 2017-2031
6.3.1. Zanamivir
6.3.2. Oseltamivir
6.3.3. Peramivir
6.3.4. Amantadine
6.3.5. Rimantadine
6.3.6. Inosine
6.3.7. Others (Laninamivir Octanoate, etc.)
6.4. Market Attractiveness, by Product Type
7. Global Influenza Medication Market Analysis and Forecast, by Distribution Channel
7.1. Introduction and Definitions
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Distribution Channel, 2023-2031
7.3.1. Hospitals
7.3.2. Clinics
7.3.3. Pharmacies
7.3.4. Others
7.4. Market Attractiveness, by Distribution Channel
8. Global Influenza Medication Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region, 2017-2031
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
9. North America Influenza Medication Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Product Type, 2017-2031
9.2.1. Zanamivir
9.2.2. Oseltamivir
9.2.3. Peramivir
9.2.4. Amantadine
9.2.5. Rimantadine
9.2.6. Inosine
9.2.7. Others (Laninamivir Octanoate, etc.)
9.3. Market Value Forecast, by Distribution Channel, 2017-2031
9.3.1. Hospitals
9.3.2. Clinics
9.3.3. Pharmacies
9.3.4. Others
9.4. Market Value Forecast, by Country, 2017-2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Product Type
9.5.2. By Distribution Channel
9.5.3. By Country
10. Europe Influenza Medication Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2017-2031
10.2.1. Zanamivir
10.2.2. Oseltamivir
10.2.3. Peramivir
10.2.4. Amantadine
10.2.5. Rimantadine
10.2.6. Inosine
10.2.7. Others (Laninamivir Octanoate, etc.)
10.3. Market Value Forecast, by Distribution Channel, 2017-2031
10.3.1. Hospitals
10.3.2. Clinics
10.3.3. Pharmacies
10.3.4. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017-2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Italy
10.4.5. Spain
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Product Type
10.5.2. By Distribution Channel
10.5.3. By Country/Sub-region
11. Asia Pacific Influenza Medication Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2017-2031
11.2.1. Zanamivir
11.2.2. Oseltamivir
11.2.3. Peramivir
11.2.4. Amantadine
11.2.5. Rimantadine
11.2.6. Inosine
11.2.7. Others (Laninamivir Octanoate, etc.)
11.3. Market Value Forecast, by Distribution Channel, 2017-2031
11.3.1. Hospitals
11.3.2. Clinics
11.3.3. Pharmacies
11.3.4. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017-2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Product Type
11.5.2. By Distribution Channel
11.5.3. By Country/Sub-region
12. Latin America Influenza Medication Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2017-2031
12.2.1. Zanamivir
12.2.2. Oseltamivir
12.2.3. Peramivir
12.2.4. Amantadine
12.2.5. Rimantadine
12.2.6. Inosine
12.2.7. Others (Laninamivir Octanoate, etc.)
12.3. Market Value Forecast, by Distribution Channel, 2017-2031
12.3.1. Hospitals
12.3.2. Clinics
12.3.3. Pharmacies
12.3.4. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017-2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Product Type
12.5.2. By Distribution Channel
12.5.3. By Country/Sub-region
13. Middle East & Africa Influenza Medication Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2017-2031
13.2.1. Zanamivir
13.2.2. Oseltamivir
13.2.3. Peramivir
13.2.4. Amantadine
13.2.5. Rimantadine
13.2.6. Inosine
13.2.7. Others (Laninamivir Octanoate, etc.)
13.3. Market Value Forecast, by Distribution Channel, 2017-2031
13.3.1. Hospitals
13.3.2. Clinics
13.3.3. Pharmacies
13.3.4. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017-2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Product Type
13.5.2. By Distribution Channel
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
14.2. Market Share Analysis, by Company (2022)
14.3. Company Profiles
14.3.1. F. Hoffmann-La Roche Ltd.,
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. SWOT Analysis
14.3.1.5. Strategic Overview
14.3.2. Teva Pharmaceutical Industries Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. SWOT Analysis
14.3.2.5. Strategic Overview
14.3.3. Sandoz International GmbH
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. SWOT Analysis
14.3.3.5. Strategic Overview
14.3.4. Sun Pharmaceutical Industries Ltd.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. SWOT Analysis
14.3.4.5. Strategic Overview
14.3.5. Mylan, Inc.
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.5.5. Strategic Overview
14.3.6. GlaxoSmithKline plc
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Financial Overview
14.3.6.4. SWOT Analysis
14.3.6.5. Strategic Overview
14.3.7. Daiichi Sankyo Company
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Financial Overview
14.3.7.4. SWOT Analysis
14.3.7.5. Strategic Overview
14.3.8. Natco Pharma
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
